Login with Linked

Follow us on

Link Linkedin Youtube

Avmapki Fakzynja Co-Pack

Avmapki Fakzynja combines two oral kinase inhibitors for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer after prior systemic therapy. It targets both MEK and FAK pathways to help control tumor growth in patients with limited treatment options.

Molecule Details :

  • Molecule Name :

    Avutometinib And Defactinib

  • Innovator :

    VERASTEM INC

  • Approval Date :

    08-May-25

  • NCE-1 Date :

    08-May-29

  • NCE Date :

    08-May-30

  • Dosage Form :

    Oral Capsule And Tablet

  • Strength :

    EQ 0.8MG BASE; EQ 200MG BASE

  • Therapeutic Category :

    Anticancer

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    31

  • 2026 :

    92

  • 2027 :

    150

  • 2028 :

    268

  • 2029 :

    405

  • 2030 :

    540

  • 2031 :

    676
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?